TransMedics Group Crescita futura
Future criteri di controllo 5/6
TransMedics Group prevede che gli utili e i ricavi cresceranno rispettivamente di 33.8% e 19.2% all'anno. Si prevede che l'EPS crescerà di 31.3% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 20.9% in 3 anni.
Informazioni chiave
33.8%
Tasso di crescita degli utili
31.3%
Tasso di crescita dell'EPS
| Medical Equipment crescita degli utili | 17.1% |
| Tasso di crescita dei ricavi | 19.2% |
| Rendimento futuro del capitale proprio | 20.9% |
| Copertura analitica | Good |
| Ultimo aggiornamento | 15 Nov 2024 |
Aggiornamenti recenti sulla crescita futura
Recent updates
TransMedics: Overreaction To Temporary Headwinds (Rating Upgrade)
Nov 12What You Can Learn From TransMedics Group, Inc.'s (NASDAQ:TMDX) P/S After Its 44% Share Price Crash
Oct 30
TransMedics: Mistakes Have Been Made, Here's My Updated Outlook
Oct 29TransMedics' Organ Care: Critical Innovation With Lofty Expectations
Oct 23TransMedics Group: This Could Be One Of The Biggest Moats In A Decade
Oct 16Returns Are Gaining Momentum At TransMedics Group (NASDAQ:TMDX)
Sep 18TransMedics: Take Profits While The Valuation Is Sky High
Sep 18TransMedics: Wide Moat Player At A Lower Valuation Than Peers
Sep 10TransMedics Group, Inc.'s (NASDAQ:TMDX) P/S Is Still On The Mark Following 25% Share Price Bounce
Aug 28TransMedics: Heart And Lungs Will Drive The Next Leg Higher
Aug 19Analysts Just Made A Meaningful Upgrade To Their TransMedics Group, Inc. (NASDAQ:TMDX) Forecasts
Aug 06TransMedics Group: Providing Long-Term Detailed Forecast And Upgrading To Buy
Aug 04TransMedics Group, Inc. Just Recorded A 66% EPS Beat: Here's What Analysts Are Forecasting Next
Aug 02TransMedics Group Stock: Too Far, Too Fast
Jul 08TransMedics: NOP, Logistics And Transport Are Key Growth Drivers But Stock Is Pricey
Jun 17TransMedics Group (NASDAQ:TMDX) Might Have The Makings Of A Multi-Bagger
Jun 10TransMedics: Transportation Supporting Growth
May 21TransMedics Group: Looking At The Road Ahead After An Exceptional Q1 (Rating Downgrade)
May 06TransMedics Group, Inc. (NASDAQ:TMDX) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Apr 24TransMedics Group: Founder Led Company With Solid Potential
Apr 19Is TransMedics Group (NASDAQ:TMDX) Using Too Much Debt?
Apr 11TransMedics Group: Emerging Medical Device Market Leader With A Long Growth Runway
Mar 19TransMedics Group: Huge Opportunity In Organ Transplants
Mar 12TransMedics: A Very Expensive Growth Stock
Feb 07With TransMedics Group, Inc. (NASDAQ:TMDX) It Looks Like You'll Get What You Pay For
Jan 23Calculating The Fair Value Of TransMedics Group, Inc. (NASDAQ:TMDX)
Jan 02Does TransMedics Group (NASDAQ:TMDX) Have A Healthy Balance Sheet?
Nov 05This Just In: Analysts Are Boosting Their TransMedics Group, Inc. (NASDAQ:TMDX) Outlook for This Year
Aug 06TransMedics Group (NASDAQ:TMDX) Has Debt But No Earnings; Should You Worry?
Aug 02TransMedics Group, Inc. (NASDAQ:TMDX) Not Lagging Industry On Growth Or Pricing
Jun 29Brokers Are Upgrading Their Views On TransMedics Group, Inc. (NASDAQ:TMDX) With These New Forecasts
May 06Is TransMedics Group (NASDAQ:TMDX) Using Too Much Debt?
Apr 27Estimating The Intrinsic Value Of TransMedics Group, Inc. (NASDAQ:TMDX)
Apr 09Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Guadagni | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2026 | 656 | 102 | 106 | 129 | 7 |
| 12/31/2025 | 548 | 56 | 49 | 79 | 10 |
| 12/31/2024 | 433 | 35 | -48 | 61 | 10 |
| 9/30/2024 | 401 | 33 | -121 | 37 | N/A |
| 6/30/2024 | 359 | 3 | -221 | 24 | N/A |
| 3/31/2024 | 297 | -10 | -230 | -8 | N/A |
| 12/31/2023 | 242 | -25 | -192 | -13 | N/A |
| 9/30/2023 | 192 | -36 | -165 | -25 | N/A |
| 6/30/2023 | 151 | -18 | -41 | -33 | N/A |
| 3/31/2023 | 119 | -28 | -47 | -36 | N/A |
| 12/31/2022 | 93 | -36 | -58 | -46 | N/A |
| 9/30/2022 | 72 | -42 | -61 | -48 | N/A |
| 6/30/2022 | 51 | -48 | -53 | -43 | N/A |
| 3/31/2022 | 39 | -47 | -45 | -40 | N/A |
| 12/31/2021 | 30 | -44 | -32 | -29 | N/A |
| 9/30/2021 | 28 | -38 | -30 | -29 | N/A |
| 6/30/2021 | 30 | -30 | -27 | -26 | N/A |
| 3/31/2021 | 25 | -28 | -30 | -29 | N/A |
| 12/31/2020 | 26 | -29 | -31 | -30 | N/A |
| 9/30/2020 | 24 | -32 | -31 | -30 | N/A |
| 6/30/2020 | 24 | -35 | -30 | -30 | N/A |
| 3/31/2020 | 26 | -36 | -34 | -33 | N/A |
| 12/28/2019 | 24 | -34 | -32 | -32 | N/A |
| 9/28/2019 | 21 | -32 | -31 | -31 | N/A |
| 6/29/2019 | 18 | -29 | -32 | -32 | N/A |
| 3/30/2019 | 15 | -26 | -27 | -27 | N/A |
| 12/29/2018 | 13 | -24 | -26 | -26 | N/A |
| 9/29/2018 | 12 | -21 | N/A | -25 | N/A |
| 6/30/2018 | 9 | -20 | N/A | -24 | N/A |
| 3/31/2018 | 8 | -20 | N/A | -23 | N/A |
| 12/30/2017 | 8 | -21 | N/A | -23 | N/A |
| 12/31/2016 | 6 | -24 | N/A | -24 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: La crescita prevista degli utili di TMDX ( 33.8% all'anno) è superiore al tasso di risparmio ( 2.6% ).
Guadagni vs Mercato: Si prevede che gli utili di TMDX ( 33.8% all'anno) cresceranno più rapidamente del mercato US ( 15.3% all'anno).
Guadagni ad alta crescita: Si prevede che gli utili di TMDX cresceranno in modo significativo nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che il fatturato di TMDX ( 19.2% all'anno) crescerà più rapidamente del mercato US ( 8.9% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di TMDX ( 19.2% all'anno) crescerà più lentamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Si prevede che il Return on Equity di TMDX sarà elevato tra 3 anni ( 20.9 %)